Table 4.

Fasting glucose and diabetes status by HBsAb serological status (HBsAb positive vs negative) in GBCS, MIDPC and data with GBCS and MIDPC pooling together

	GBCS		MIDPC		GBCS+MIDPC
	β (95% CI)	P value	β (95% CI)	P value	β (95% CI)	P value
Fasting glucose, mmol/L
Crude model	−0.01 (−0.06 to 0.05)	0.83	0.04 (−0.08 to 0.16)	0.54	0.02 (−0.05 to 0.08)	0.60
Model 1	−0.01 (−0.06 to 0.05)	0.83	0.03 (−0.09 to 0.16)	0.58	0.02 (−0.05 to 0.08)	0.62
Model 2	−0.01 (−0.06 to 0.05)	0.84	0.08 (−0.06 to 0.21)	0.26	0.04 (−0.03 to 0.11)	0.29
OR (95% CI)		OR (95% CI)		OR (95% CI)
Diabetes, yes vs no
Crude model	0.88 (0.67 to 1.15)	0.34	0.97 (0.85 to 1.11)	0.64	0.95 (0.84 to 1.07)	0.40
Model 1	0.88 (0.68 to 1.15)	0.35	0.96 (0.84 to 1.10)	0.55	0.95 (0.84 to 1.07)	0.37
Model 2	0.85 (0.65 to 1.12)	0.24	1.00 (0.86 to 1.16)	0.95	0.98 (0.86 to 1.12)	0.78

Model 1: adjusting for age and sex.

Model 2: additionally adjusting for education, occupation, smoking status, alcohol use, physical activity, BMI and study sample source, as appropriate.

BMI, body mass index; GBCS, Guangzhou Biobank Cohort Study; HBsAg, hepatitis B surface antigen; MIDPC, Major Infectious Disease Prevention and Control.